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Cutaneous delivery of therapeutics represents a pro-
ven and attractive option for treating a variety of
dermatologic conditions with minimal systemic side
effects. Although there have been many innovations in
drug delivery systems, the number of effective cuta-
neous drugs remains small, primarily because of the
stratum corneum permeability barrier. Overcoming
this barrier safely and reversibly to deliver large
hydrophilic drugs cutaneously is one of the major
challenges in the field of dermatologic therapy.
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A topically applied substance has basically three possibilities
to penetrate into the skin: transcellular, intercellular, and
follicular. The transfollicular path has been largely ignored
because hair follicles constitute only 0.1% of the total skin.
Nonetheless, this method has great potential for skin treatment
by providing a deeper penetration and absorption of com-
pounds than transcellular route, and also can affect adnexal
structures. Increased accumulation of drugs in the pilosebac-
eous unit could potentially treat alopecia, acne, and other skin
diseases more efficiently. Here, we present a summary of the
latest technologies used to increase cutaneous delivery
through the three different routes outlined above, delineating
various chemical and physical methods as well as reviewing
various drug delivery systems, including liposomes, micro-
spheres, and nanoparticles.
Skin, the largest organ of the human body, offers a painless
and compliant interface for cutaneous drug administration. As
compared with injections and oral delivery routes, cutaneous
drug delivery increases patient compliance, avoids metabo-
lism by the liver, provides sustained and controlled delivery
over long time periods, concentrates the active agents at the
site of disease, and prevents systemic side effects. Recent
advances in biotechnology have laid the groundwork for very
promising, potent, and highly specific molecular targeting
therapies. Although innovations in drug delivery systems have
enabled the successful clinical use of some of these novel
pharmaceuticals, the number of effective cutaneous drugs
remains small. And yet, after nearly four decades of extensive
study, the success of this technology remains limited, with
only a few transdermal products available, all of them based
on low-molecular-weight lipophilic drugs (Bos and Meinardi,
2000). Currently, drugs administered across the skin share
three constraining characteristics: low molecular mass
(o500 Da), high lipophilicity (oil soluble), and small
required dose (mg) (Prausnitz et al., 2004). This is because
the stratum corneum (SC), which evolved to protect the
body from toxins, is nearly impermeable to the movement of
foreign molecules across it (Scheuplein and Blank, 1971).
Overcoming this barrier safely and reversibly to deliver large
hydrophilic drugs cutaneously is one of the major challenges
in the field of dermatologic therapy.
A topically applied substance has basically three possibi-
lities to penetrate into the skin: transcellular (through the cell),
intercellular (in between the cells), and follicular (through
hair follicles) (Geusens et al., 2011). Intercellular penetration
requires transport through extracellular lipid matrix as well as
internalization into the cell. Given the SC is highly imper-
meable to most molecules on the basis of size, hydrophilicity,
lipophilicity, and charge, it is necessary to alter temporarily
the barrier properties of skin for effective delivery of the
desired drugs. Strategies to improve drug delivery can be
broadly subdivided into chemical, biochemical, and physical
approaches (Figure 1). Chemical strategies have included the
development of novel chemical enhancers, which alter the
lipid structure of the SC, including solvents (propylene glycol,
DMSO), fatty acid esters (oleic acid), and surfactants (SDS)
(Karande et al., 2005). Chemical enhancers increase skin
permeability by several mechanisms: (1) disrupting the SC
lipid organization, making it permeable (many enhancers
operate mainly in this way such as azone, terpenes, fatty
acids, DMSO, and alcohols); (2) extracting lipids, making the
horny layer more permeable through forming aqueous
channels (DMSO, ethanol); (3) interacting with keratin in
corneocytes, opening up the dense protein structure, making it
more permeable (e.g. DMSO, ionic surfactants). Biochemical
approaches include intracellular delivery peptides for gene
delivery for small interfering RNAs (Deshayes et al., 2008;
Gooding et al., 2012) and the development of nanodelivery
vehicles that can deliver their payload to the deeper layers of
the skin. These vehicles include nanoparticles (nanosized
colloidal structures composed of synthetic or semisynthetic
polymers, lipids, metals, and ceramics), liposomes (colloidal
particles, typically consisting of lipid molecules form
concentric layers that may entrap and deliver drugs to the
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skin), microspheres (free-flowing powders consisting of
proteins or synthetic polymers, biodegradable in nature,
o200mm) (Papakostas et al., 2011; DeLouise, 2012), etc.
These particles can be functionalized with a variety of
moieties, including DNA and other nucleic acids, poly-
ethylene glycol (PEG), protein, magnetic resonance imaging
active agent, photosensitizer, polymeric coating, and targeting
agents (Vatansever et al., 2012). The unique kinetics and
ability to functionalize these particles have made these
particles very attractive for drug delivery applications.
Physical methods include the use of external forces such as
high-frequency sound waves in ultrasound or electric currents
in iontophoresis to create gaps in the SC (Mitragotri et al.,
1995; Banga et al., 1999), physical disruption of the SC via
minimally invasive microneedles (van der Maaden et al.,
2012), the use of ablative laser therapy for dermal delivery
(Gomez et al., 2012; Bloom et al., 2013), and chemical
depilation–induced anagen for hair follicles (Domashenko
et al., 2000), etc. Recently, various laser therapies such as frac-
tional and ablative lasers have been explored to create
temporary barrier impairment, including channels for
transport and/or ablating the SC and allowing for enhanced
drug delivery (Lee et al., 2001; Hædersdal et al., 2010; Lee
et al., 2011).
The transfollicular path has been largely ignored because
hair follicles constitute only 0.1% of the total skin. None-
theless, the optimization of drug delivery to and via the hair
follicles is gaining more and more importance as it has been
recognized that the hair follicles are an interesting target
site for topical applications. Drug delivery to hair follicles is
likely dependent on the physicochemical properties of the
drugs, the vehicles used in the formulation, as well as on
the activity status, size, and density of the hair follicle.
The available targets included surrounding capillaries and
antigen-presenting cells, sebaceous glands, and stem cells in
the bulge region of the hair follicle (Patzelt and Lademann,
2013). Transfollicular delivery has great potential for skin
treatment by providing a deeper penetration and absorption of
compounds than transcellular route, and also can affect sweat
glands or the pilosebaceous unit (Teichmann et al., 2005;
Blume-Peytavi and Vogt, 2011). Many studies suggest that the
follicular pathway, in contrast to the conventional transdermal
pathway, is especially favorable for highly hydrophilic and
high-molecular-weight substances (Mitragotri, 2003), as well
as particle-based drug delivery systems (Alvarez-Roman et al.,
2004). Methods for follicular delivery include penetration
enhancement via liposomal delivery of drug (Verma et al.,
2004; Jung et al., 2006), the use of drug-loaded microspheres
(Alvarez-Roman et al., 2004), or transdermal delivery of
particles that will interact with follicular cell targets
(Chourasia and Jain, 2009). Challenges for follicular delivery
include the inner and outer root sheets, the flow of sebum into
the hair follicle, the interaction between the drug and the
sebum, as well as the physicochemical properties of the
vehicle (Illel, 1997; Chourasia and Jain, 2009). Nonetheless,
studies concerning nanoparticles that can reach deeper parts
of the follicles after a short time prove that the penetration
process overcomes sebum flow (Lademann et al., 2006).
An area that is gaining importance in follicular drug delivery
is the use of particulate drug delivery systems (such as
nanoparticles and microparticles) as they increase drug pene-
tration into the hair follicle openings and can act as depots
for sustained drug release within the hair follicle (Papakostas
et al., 2011). Nanoparticle formulations are gaining more
preference over aqueous alcohol solutions used so far for the
treatment of hair disorders such as androgenetic alopecia
and alopecia areata. Indeed, encapsulating hair-growing
ingredients in PLGA (poly(D,L-lactide-co-glycolide)) particles
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Figure 1. Summary of methods for optimizing cutaneous drug delivery.
TN Tran
Cutaneous Drug Delivery: An Update
S68 Journal of Investigative Dermatology Symposium Proceedings (2013), Volume 16
increased their permeation within hair follicle regions 2.0- to
2.5-fold more than in the case of the control aqueous solutions
(Tsujimoto et al., 2007). The follicular penetration of nano-
and microparticles depends on the sizes of the particle;
therefore, particle-based delivery systems can be used to
target specific regions of the follicular duct. In addition,
nanoparticles or nanoparticulate delivery systems can also
incorporate immunomodulatory agents, allowing for topical
administrations of medications that could otherwise have
severe adverse systemic side effects. For example, liposomal
formulations of cyclosporin A induced visible hair regrowth in
rats, thus showing a potential for new topical treatments of
alopecia areata in humans (Vogt et al., 2006). Gene therapy
has also been recently demonstrated using small interfering
RNA encapsulated in biodegradable cationized gelatin
microspheres injected in a murine model of disease,
resulting in remission of the alopecia areata (Nakamura
et al., 2008). Challenges, however, remain in topical applica-
tion of large molecules such as small interfering RNAs and
more study are needed. Promising concepts to optimize hair
follicle delivery include the application of external or internal
stimuli for controlled drug release from the particles such as
the cocomitant application with protease or the usage of gold
nanoparticles in combination with near-infrared irradiation
(Patzelt and Lademann, 2013). Novel particle-based drug
delivery system may provide promising active follicular tar-
geting of disease-related cell populations in the hair follicle.
Increased accumulation of drugs in the pilosebaceous unit
could potentially treat alopecia, acne, and other skin diseases
more efficiently. Ultimately, as technology leads to improved
therapeutic options, we may see more successful treatments
for alopecia areata, a disease that can be both challenging and
frustrating for patients and physicians.
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